RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:New Press Release - Theralase(R) Provides Update on Bladder Cancer Clinical Studyi like the optimism expressed on the board with projected stock prices shooting up before the end of this year. I get it that we are close to getting BTD and possibly AA. It looks from RDW's statement that we have 57 evaluable patients and I believe he mentioned that we need 100 evaluable patients in an earlier report. Reading his latest statement I think the timelines are being pushed further. complete patient enrollment by end of 2024 and complete assessment vaguely pointing to 2026. Here is the quote from RDW's latest that I am refering to.
Theralase® hopes to complete patient enrollment with accompanying administration of the primary Study II Treatment by year end 2024. If successful, this will allow the Company the ability to complete assessment of the primary, secondary and tertiary endpoints of these patients by 2026. Based on the clinical data to date, Theralase® is investigating potential partnerships for commercialization, financing and distribution of this ACT technology on an international basis. Theralase® looks forward to commercializing this world-class technology for the benefit of all shareholders."